Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein

International Journal of Molecular Medicine

Volumn 19, Issue 5, 2007, Pages 841-849

  Beerens, A M J ^a   Rots, M G ^a   De Vries, E F J ^b   Haisma, H J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Fusion protein; HSV TK; Intercellular trafficking; Protein transduction domain; Suicide gene therapy; VP22 tegument protein

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX VIRUS TYPE 1 PROTEIN VP22; HYBRID PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PROTEIN TRANSPORT; SUICIDE TRANSGENE; TRANSGENE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; FLOW CYTOMETRY; GANCICLOVIR; GENES, TRANSGENIC, SUICIDE; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; TRANSGENES; VIRAL STRUCTURAL PROTEINS;

EID: 34248580142     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.5.841     Document Type: Article

References (65)

1. Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T and Butler EB: Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int J Radiat Oncol Biol Phys 51: 605-613, 2001.
2. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
3. Lefesvre P, Attema J and van Bekkum D: A comparison of efficacy and toxicity between electroporation and adenoviral gene transfer. BMC Mol Biol 3: 12, 2002.
4. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and Yla-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10: 967-972, 2004.
5. Klatzmann D, Cherin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, Boccaccio C, Salzmann JL and Herson S: A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 9: 2585-2594, 1998.
6. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR and Castro MG: Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65: 7194-7204, 2005.
7. Pandha H, Eaton J, Greenhalgh R, Soars D and Dalgleish A: Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ ganciclovir suicide gene therapy. Cancer Gene Ther 12: 572-578, 2005.
8. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
9. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M and Yla-Herttuala S: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11: 2197-2205, 2000.
10. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD and Jacobs AH: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54: 479-487, 2003.
11. Black ME, Kokoris MS and Sabo P: Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61: 3022-3026, 2001.
12. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart HJ, Merritt J and Chada S: Intratumoral injection of INGN 241, a non-replicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11: 160-172, 2005.
13. Schagen FH, Ossevoort M, Toes RE and Hoeben RC: Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50: 51-70, 2004.
14. Oosterhoff D, Pinedo HM, van der Meulen-Muileman IH, de Graaf M, Sone T, Kruyt FA, van Beusechem VW, Haisma HJ and Gerritsen WR: Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br J Cancer 87: 659-664, 2002.
15. de Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ and Boven E: Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Hum Gene Ther 15: 229-238, 2004.
16. Beerens AM, Al Hadithy AF, Rots MG and Haisma HJ: Protein transduction domains and their utility in gene therapy. Curr Gene Ther 3: 486-494, 2003.
17. Derossi D, Joliot AH, Chassaing G and Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450, 1994.
18. Elliott G and O'Hare P: Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell 88: 223-233, 1997.
19. Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988.
20. Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188, 1988.
21. Perez F, Joliot A, Bloch-Gallego E, Zahraoui A, Triller A and Prochiantz A: Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 102: 717-722, 1992.
22. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B and Barsoum J: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91: 664-668, 1994.
23. Wadia JS, Stan RV and Dowdy SF: Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315, 2004.
24. Rothbard JB, Jessop TC and Wender PA: Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev 57: 495-504, 2005.
25. Elliott GD and Meredith DM: The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J Gen Virol 73: 723-726, 1992.
26. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI and O'Hare P: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6: 12-21, 1999.
27. Lai Z, Han I, Zirzow G, Brady RO and Reiser J: Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors. Proc Natl Acad Sci USA 97: 11297-11302, 2000.
28. Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD and Rehemtulla A: Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 13: 127-137, 2006.
29. Falnes PO, Wesche J and Olsnes S: Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 40: 4349-4358, 2001.
30. Lundberg M and Johansson M: Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 291: 367-371, 2002.
31. Hakkarainen T, Wahlfors T, Merilainen O, Loimas S, Hemminki A and Wahlfors J: VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct. J Gene Med 7: 898-907, 2005.
32. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
33. Hospers GA, Calogero A, van Waarde A, Doze P, Vaalburg W, Mulder NH and de Vries EF: Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography. Cancer Res 60: 1488-1491, 2000.
34. Evan GI, Lewis GK, Ramsay G and Bishop JM: Isolation of monoclonal antibodies specific for human c-myc protooncogene product. Mol Cell Biol 5: 3610-3616, 1985.
35. Hinds TA, Compadre C, Hurlburt BK and Drake RR: Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities. Biochemistry 39: 4105-4111, 2000.
36. Zavaglia D, Lin EH, Guidetti M, Pluquet O, Hainaut P, Favrot MC and Coll JL: Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo. J Gene Med 7: 936-944, 2005.
37. Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M and Lauer UM: Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 8: 1654-1664, 2001.
38. Brignati MJ, Loomis JS, Wills JW and Courtney RJ: Membrane association of VP22, a herpes simplex virus type 1 tegument protein. J Virol 77: 4888-4898, 2003.
39. Fittipaldi A and Giacca M: Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57: 597-608, 2005.
40. Roy V, Qiao J, de Campos-Lima P and Caruso M: Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther 12: 169-176, 2005.
41. Lundberg M and Johansson M: Is VP22 nuclear homing an artifact? Nat Biotechnol 19: 713-714, 2001.
42. Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M and Lauer UM: Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1: 265-274, 1999.
43. Green KL, Southgate TD, Mulryan K, Fairbairn LJ, Stern PL and Gaston K: Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther 17: 147-157, 2006.
44. Zavaglia D, Favrot MC, Eymin B, Tenaud C and Coll JL: Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther 10: 314-325, 2003.
45. Sheridan PJ, Lawrie A, Crossman DC, Holt CM and Newman CM: VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following nonviral transfection. J Gene Med 7: 375-385, 2005.
46. Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO and Johnson DE: Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus. J Virol 75: 8733-8741, 2001.
47. Morris SJ, Smith H and Sweet C: Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role. Arch Virol 147: 961-979, 2002.
48. Lundberg M, Wikstrom S and Johansson M: Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 8: 143-150, 2003.
49. Kong B, Wang W, Liu C, Song L, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Wang B, Wei MQ and Yang Q: Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo 17: 153-156, 2003.
50. Liu CS, Kong B, Xia HH, Ellem KA and Wei MQ: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 3: 145-152, 2001.
51. Greco O, Joiner MC, Doleh A and Scott SD: VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Ther 12: 974-979, 2005.
52. Ye D, Xu D, Singer AU and Juliano RL: Evaluation of strategies for the intracellular delivery of proteins. Pharm Res 19: 1302-1309, 2002.
53. Derer W, Easwaran HP, Knopf CW, Leonhardt H and Cardoso MC: Direct protein transfer to terminally differentiated muscle cells. J Mol Med 77: 609-613, 1999.
54. Stroh C, Held J, Samraj AK and Schulze-Osthoff K: Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the Herpes virus protein VP22. Oncogene 22: 5367-5373, 2003.
55. Qiu Z, Harms JS, Zhu J and Splitter GA: Bovine herpes virus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 78: 4224-4233, 2004.
56. Rutjes SA, Bosma PJ, Rohn JL, Noteborn MH and Wesseling JG: Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins. J Mol Med 81: 558-565, 2003.
57. Zender L, Kuhnel F, Kock R, Manns M and Kubicka S: VP22- mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 9: 489-496, 2002.
58. Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M and Kubicka S: Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 123: 608-618, 2002.
59. Soden J, Stevens A and Ray DW: Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation. J Endocrinol 172: 615-625, 2002.
60. Li Y, Rosal RV, Brandt-Rauf PW and Fine RL: Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun 298: 439-449, 2002.
61. Phelan A, Elliott G and O'Hare P: Intercellular delivery of functional p53 by the herpes virus protein VP22. Nat Biotechnol 16: 440-443, 1998.
62. Gunther M, Wagner E and Ogris M: Specific targets in tumor tissue for the delivery of therapeutic genes. Curr Med Chem Anticancer Agents 5: 157-171, 2005.
63. Vose JM: Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9: 160-172, 2004.
64. Bruell D, Stocker M, Huhn M, Redding N, Kupper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R and Barth S: The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23: 1179-1186, 2003.
65. Liu S, Bugge TH and Leppla SH: Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 276: 17976-17984, 2001.